On November 11, 2019 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform, reported that Sean McCarthy, D.Phil., president, chief executive officer and chairman, will participate at the following healthcare conferences (Press release, CytomX Therapeutics, NOV 11, 2019, View Source [SID1234550858]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies 2019 London Healthcare Conference

Dr. McCarthy will present a Corporate Update

Date: Wednesday, November 20, 2019
Time: 1:20 p.m. GMT / 8:20 a.m. ET
Location: London, United Kingdom

Piper Jaffray 31st Annual Healthcare Conference

Dr. McCarthy will participate in a Fireside Chat

Date: Tuesday, December 3, 2019
Time: 1:00 p.m. ET
Location: New York, New York
Live audio webcast of the corporate presentation will be available through the "Investors & News" section of CytomX’s website. An archived replay will be available for 60 days following the event.